Literature DB >> 6681655

National surveillance for Guillain-Barré syndrome: January 1978-March 1979.

E S Hurwitz, R C Holman, D B Nelson, L B Schonberger.   

Abstract

Between January 1, 1978, and March 31, 1979, 1,034 cases of Guillain-Barré syndrome (GBS) were reported to the Centers for Disease Control by the 1,813 American Academy of Neurology sentinel physicians who participated in the national GBS surveillance program. A direct correlation was observed between increasing age and the age-specific attack (incidence) rates. Based on the cases observed and the total US population, age-adjusted attack rates were statistically higher in males (0.52 per 100,000) than in females (0.40). Rates for whites were 0.44 and those for blacks 0.28 per 100,000; although the difference is statistically significant, uncertainties as to the true denominators by race preclude acceptance of these differences as valid. Sixty-seven percent, or 682 of the patients, reported that they had had an antecedent illness within 8 weeks before onset of GBS, and among them the peak period of onset of GBS was in the second week after the onset of the prior illness. There were also 52 patients (5%) who had undergone surgery and 45 (4.5%) who had received vaccinations, both within the 8 weeks before onset of GBS. However, the high proportions of antecedent illness in these groups (45% of those operated and 53% of those vaccinated) made attribution of GBS to the procedures tenuous. Risk of GBS in patients who reported receiving a swine influenza vaccination in 1976 was no greater than in those who reported that they did not receive this vaccine.

Entities:  

Mesh:

Year:  1983        PMID: 6681655     DOI: 10.1212/wnl.33.2.150

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Enhancing public confidence in vaccines through independent oversight of postlicensure vaccine safety.

Authors:  Daniel A Salmon; Lawrence H Moulton; Neal A Halsey
Journal:  Am J Public Health       Date:  2004-06       Impact factor: 9.308

2.  Relationship of adjuvants and swine influenza vaccine to experimental neuropathy in rabbits.

Authors:  H C Powell; A P Mizisin; C A Wiley; M K Morey; R A Hughes
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

3.  Guillain-Barré syndrome following zimeldine treatment.

Authors:  J Fagius; P O Osterman; A Sidén; B E Wiholm
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-01       Impact factor: 10.154

Review 4.  Immunology of Guillain-Barré syndrome.

Authors:  I Steiner; O Abramsky
Journal:  Springer Semin Immunopathol       Date:  1985

Review 5.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

6.  Clinical factors associated with Guillain-Barré syndrome following surgery.

Authors:  Sara Hocker; Elanagan Nagarajan; Mark Rubin; Eelco F M Wijdicks
Journal:  Neurol Clin Pract       Date:  2018-06

7.  Acute flaccid paralysis and West Nile virus infection.

Authors:  James J Sejvar; A Arturo Leis; Dobrivoje S Stokic; Jay A Van Gerpen; Anthony A Marfin; Risa Webb; Maryam B Haddad; Bruce C Tierney; Sally A Slavinski; Jo Lynn Polk; Victor Dostrow; Michael Winkelmann; Lyle R Petersen
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

Review 8.  Vaccines for preventing influenza in healthy adults.

Authors:  Vittorio Demicheli; Tom Jefferson; Eliana Ferroni; Alessandro Rivetti; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

Review 9.  Vaccines for preventing influenza in the elderly.

Authors:  Vittorio Demicheli; Tom Jefferson; Carlo Di Pietrantonj; Eliana Ferroni; Sarah Thorning; Roger E Thomas; Alessandro Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.